Assuntos
Neoplasias Ósseas/diagnóstico por imagem , Neoplasias Cardíacas/diagnóstico por imagem , Linfoma Difuso de Grandes Células B/diagnóstico por imagem , Neoplasias do Mediastino/diagnóstico por imagem , Neoplasias do Sistema Nervoso Periférico/diagnóstico por imagem , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Murinos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Feminino , Fluordesoxiglucose F18 , Neoplasias Cardíacas/tratamento farmacológico , Humanos , Linfonodos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Neoplasias do Mediastino/tratamento farmacológico , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Prednisona/uso terapêutico , Compostos Radiofarmacêuticos , Rituximab , Vincristina/uso terapêuticoAssuntos
Cardiomiopatias/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Sarcoidose/diagnóstico por imagem , Adulto , Técnicas de Imagem Cardíaca , Protocolos Clínicos , Dieta com Restrição de Carboidratos , Dieta Hiperlipídica , Feminino , Fluordesoxiglucose F18 , Humanos , Pessoa de Meia-Idade , Imagem Multimodal , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios XRESUMO
Osseous metastatic disease from malignancy is a common occurrence with significant patient morbidity and mortality as well as increasing health care expenditures. Patient management plans frequently change with the identification of skeletal metastasis and the upstaging of disease status. Bone scintigraphy remains the current mainstay of diagnostic imaging procedures in nuclear medicine for the early detection of skeletal metastasis owing to their high sensitivity. Emerging positron tracers and the increasing use and availability of hybrid single-photon emission computed tomography and positron emission tomography (PET)/computed tomography machines enable physicians to diagnose metastatic disease in bones with superior accuracy. This review introduces the basics of PET and the commonly used positron tracers used to evaluate skeletal metastases.
Assuntos
Neoplasias Ósseas/diagnóstico , Neoplasias Ósseas/secundário , Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada por Raios X/métodos , Neoplasias da Mama/patologia , Carcinoma Neuroendócrino/patologia , Feminino , História Antiga , Humanos , Neoplasias Renais/patologia , Neoplasias Pulmonares/patologia , Imageamento por Ressonância Magnética , Masculino , Mieloma Múltiplo/patologia , Neoplasias da Próstata/patologia , Neoplasias da Glândula Tireoide/patologiaAssuntos
Corpo Caloso/patologia , Sarcoma Mieloide/diagnóstico , Sarcoma Mieloide/patologia , Corpo Caloso/diagnóstico por imagem , Fluordesoxiglucose F18 , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Sarcoma Mieloide/diagnóstico por imagem , Tomografia Computadorizada por Raios XRESUMO
OBJECTIVE: 2-deoxy-2-[¹8F]fluoro-D-glucose positron emission tomography/computed tomography ([¹8F] FDG PET/CT) has become an established imaging tool in oncology and is now emerging in the field of infectious disease. The aim of this study is to assess the value of fluorine [¹8F] FDG PET/CT in the investigation of patients with fever of unknown origin (FUO). METHODS: [¹8F] FDG PET/CT scans and clinical data of 12 patients were reviewed. These patients met the revised definition criteria of FUO (febrile illness of greater than 3 weeks duration, temperature greater than 38.3°C and no diagnosis after at least 3 days of in-patient investigation or 2 weeks of outpatient investigation). A retrospective analysis of our local database was performed and evaluated for the diagnostic contribution of [¹8F] FDG PET/CT scans. RESULTS: An infective cause of the FUO was found in four (33.3%) patients, a neoplasm in two (16.7%) patients, non-infectious inflammatory disease or autoimmune in one (8.3%) patient. A definitive causative agent could not be found in five (41.7%) patients despite extensive investigations.In all, five (41.6%) patients had a PET/CT scan that was abnormal and was deemed 'helpful' as part of the investigation that pointed to the final diagnosis. Two (16.7%) patients had abnormal scans, which were deemed 'not-helpful' for the final diagnosis. CONCLUSION: [¹8F] FDG PET/CT can be helpful in some patients with FUO. This study adds value to the limited data published so far on this subject.
